# Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/semaglutide-reduced-risks-of-major-kidney-outcomes-irrespective-of-ckd-severity/

## Facts

| Field | Value |
| --- | --- |
| Author Names | R E Schmieder,K R Tuttle,E Sokareva,B Rayner,G Pugliese,R E Pratley,V Perkovic,K W Mahaffey,N Kashihara,O K Jeppesen,J Gumprecht,R Correa-Rotter,D Cherney,H Bosch-Traberg,M Arici,P Rossing,JF. E. Mann |
| Citations | 0 |
| DOI | 10.1055/s-0046-1820049 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W7160083169 |
| Type | conference-paper |
| Year | 2026 |

## Paper authors

- [V Perkovic](https://scholariq.org/researchers/v-perkovic/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.